Expertise in
7
conditions

Oliver Peters

Berlin, BE, DE 
Expertise in
7
conditions
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Oliver Peters practices in Berlin, Germany. Mr. Peters is highly rated in 7 conditions, according to our data. His top areas of expertise are Dementia, Alzheimer's Disease, Developmental Dysphasia Familial, and Memory Loss.

His clinical research consists of co-authoring 235 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Berlin, BE, Germany
Other Locations
Magdeburg, ST, Germany
Munich, BY, Germany
Bonn, NW 53127, Germany
Dresden, SN, Germany
Rostock, MV, Germany
Charité Universitätsmedizin Berlin
Mitte, BE, Germany
Goettingen, NI, Germany
Aachen, NW, Germany
Duesseldorf, NW 40225, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease.
A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects With MCI and Mild Dementia Due to Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: PQ912 Glutaminyl Cyclase Enzyme Inhibitor
Study Phase: Phase 2
A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease
A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease
Enrollment Status: Completed
Publish Date: September 04, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients
Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients
Enrollment Status: Unknown
Publish Date: January 27, 2020
Intervention Type: Drug
Study Drug: Simvastatin
Study Phase: Phase 4
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease
A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 14, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

234 Total Publications

An Unsupervised XAI Framework for Dementia Detection with Context Enrichment.
An Unsupervised XAI Framework for Dementia Detection with Context Enrichment.
Journal: medRxiv : the preprint server for health sciences
Published: June 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Peters's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile